Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study

Sanne Y. Smith-Apeldoorn, Jolien K. E. Veraart, Henricus G. Ruhé, Marije aan het Rot, Jeanine Kamphuis, Marrit K. de Boer and Robert A. Schoevers

**Background**

Intravenous infusion of ketamine can produce rapid and large symptom reduction in patients with treatment-resistant depression (TRD) but presents major obstacles to clinical applicability, especially in community settings. Oral esketamine may be a promising addition to our TRD treatment armamentarium.

**Aims**

To explore the safety, tolerability and potential clinical effectiveness of a 3-week treatment with repeated, low-dose oral esketamine.

**Method**

Seven patients with chronic and severe TRD received 1.25 mg/kg generic oral esketamine daily, over 21 consecutive days. Scores on the Systematic Assessment for Treatment Emergent Events (SAFTEE), Community Assessment of Psychotic Experiences (CAPE), Clinician Administered Dissociative States Scale (CADSS) and Hamilton Rating Scale for Depression (HRSD) instruments, as well as blood pressure and heart rate, were repeatedly assessed.

**Results**

Treatment with oral esketamine was well-tolerated. No serious side-effects occurred, and none of the participants discontinued treatment prematurely. Psychotomimetic effects were the most frequently reported adverse events. Mean HDRS score decreased by 16.5%, from 23.6 to 19.7. Three participants showed reductions in HDRS scores above the minimum clinically important difference (eight-point change), of whom two showed partial response. No participants showed full response or remission.

**Conclusions**

These results strengthen the idea that oral esketamine is a safe and well-tolerated treatment for patients with chronic and severe TRD, but therapeutic effects were modest. Results were used to design a randomised controlled trial that is currently in progress.

**Keywords**

Esketamine; oral administration; treatment-resistant depression; tolerability; safety.

**Copyright and usage**

© The Author(s), 2021. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

Depression is one of the most impactful conditions worldwide in terms of individual suffering, lost productivity and healthcare costs. Unfortunately, response to treatment is often unsuccessful. Antidepressant medication and psychotherapy are ineffective in approximately 30% of patients. Although electroconvulsive therapy (ECT) is more effective, cognitive side-effects limit its use and there is a relatively high risk of relapse. Hence, there is a pressing need to develop new treatment strategies for depression generally, and for treatment-resistant depression (TRD) specifically.

**Ketamine for depression**

Multiple lines of evidence support the idea that ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, is an effective treatment for depression. A single intravenous infusion of a subanaesthetic dose can produce rapid and large symptom reduction in patients with unipolar and bipolar TRD, which generally lasts for about 1 week. These effects can be extended with repeated intravenous administration. However, this continuation procedure is relatively invasive and costly, and often brings about acute psychiatric (e.g. dissociation, anxiety, agitation) and somatic (e.g. headache, dizziness, cardiovascular) side-effects. These disadvantages present major obstacles to clinical use, especially in community settings.

To date, several studies have reported on the antidepressant properties of oral ketamine. They suggest that oral ketamine may also be effective in TRD, and that side-effects are well-tolerated. Moreover, chronic pain management data indicate that oral ketamine may safely be used for longer periods of time, including at home. Importantly, oral administration is associated with a lower risk of misuse compared with other routes of administration. Therefore, oral ketamine may be a suitable alternative for intravenous ketamine in the treatment of TRD.

**Esketamine**

It should be noted that in most studies conducted to date, ketamine has been administered as a racemic mixture comprising its R-(−) enantiomer (arketamine) and S-(+)-enantiomer (esketamine). Esketamine’s NMDA receptor-binding affinity is three to four times higher than that of arketamine. It has been assumed that the majority of ketamine’s antidepressant properties result from NMDA receptor antagonism and the consequent impact on glutamate neurotransmission. This would imply that esketamine could yield a better therapeutic effect than arketamine. Indeed, rapid and robust antidepressant effects of esketamine have been observed, and in 2019 an intranasal application of esketamine was approved by the USA Food and Drug Administration. However, the efficacy and safety of this esketamine nasal spray have been questioned, and the spray is currently expensive, limiting its widespread use. Comparably, oral (es)ketamine is widely available.
Given the advantages of oral over intravenous administration and indications for therapeutic efficacy of esketamine, oral esketamine may be a promising addition to treatment options for TRD. The aim of the present study was to explore the safety and tolerability of a 3-week treatment with oral esketamine in patients with chronic and severe TRD, and determine its potential clinical effectiveness.

Method

Sample

Participants were recruited at the Department of Psychiatry at the University Medical Center Groningen. We enrolled adults who met DSM-IV criteria for a major depressive episode (MDE). Additional inclusion criteria were severe symptom severity (score of >18 on the 17-item Hamilton Rating Scale for Depression (HRSD)) and TRD (insufficient response to four or more antidepressants or ECT during lifetime, given for ≥4 weeks in standard therapeutic doses). Exclusion criteria were psychotic features; past or current psychotic disorder; current substance dependence; primary diagnosis of personality disorder; and any contraindication for esketamine treatment, according to its Summary of Product Characteristics.

Assessments

Safety and tolerability of treatment were assessed weekly by a staff medical doctor, using the Systematic Assessment for Treatment Emergent Events (SAFTEE), the Community Assessment of Psychic Experiences (CAPE) and the Clinician Administered Dissociative States Scale (CADSS). We assessed the occurrence of hypertension (systolic blood pressure >160; diastolic blood pressure >110) and tachycardia (beats per minute >100) daily. A medical doctor examined change in depressive symptom severity, expressed as a change in total HRSD score between pre-treatment and end of treatment (3 weeks) and between end of treatment and follow-up (2 weeks).

Treatment protocol

Participants were prescribed an oral solution containing 10 mg/mL generic esketamine three times a day, over 21 days. During the first 4 days, dosages were gradually increased (if well-tolerated) by 0.25 mg/kg per day, from 0.5 mg/kg per day up to a maximum of 1.25 mg/kg per day. The first doses were taken at the clinic and subsequent doses could be taken at home, depending on the participant’s clinical state.

The maximum dose of 1.25 mg/kg per day was based on previous intravenous studies, most of which have used 0.5 mg/kg racemic ketamine. Given that 0.5 mg racemic ketamine includes 0.25 mg esketamine, esketamine accounts for 80% of the NMDA receptor antagonism of racemic ketamine and the bioavailability of oral esketamine is estimated to be around 20%. The maximum dose would be equivalent to 1.5 mg/kg. However, given potential additional pharmacodynamic properties of ketamine’s metabolites and evidence that 1.25 mg/kg per day oral esketamine could be effective in TRD, we used a cautious maximum daily dose of 1.25 mg/kg per day to prevent overtreatment and associated side-effects. The daily dose was divided into three administrations, preventing high peak blood concentrations. This is expected to minimise acute side-effects, and is in line with ketamine use in the field of pain management, where there is ample experience with oral application of ketamine, and with several previous studies on oral ketamine in patients with depressive disorders.

This treatment protocol was submitted to the Medical Ethics Review Board of the University Medical Center Groningen (approval number M17.217644), which exempted it from review under the Dutch Medical Research involving Human Subjects Act 1999. Our protocol was considered a compassionate use programme, allowing the use of an unauthorised medicine under strict conditions. Before providing written consent, participants received an oral and written explanation of the procedures, potential benefits and potential risks. Participants continued any antidepressant treatment they had been receiving before the start of esketamine, including psychotherapy.

Data processing

The incidence of adverse events was calculated by comparing SAFTEE, CAPE and CADSS data during treatment and pre-treatment. Moderate discomforts (SAFTEE) were defined as an increase of ‘not present’ to ‘moderate’, or ‘mild’ to ‘severe’. Severe discomforts were defined as an increase of ‘not present’ to ‘severe’. The onset of new delusional thoughts (CAPE) or dissociative symptoms (CADSS) was defined as a change of ‘not present’ at baseline to ‘present’ during treatment, regardless of the severity. Increase of delusional thoughts or dissociative symptoms was defined as an increase of at least two levels of severity of pre-existing symptoms. We defined the minimum clinically important difference (MCID) as ≥8-point decrease in HRSD score, remission as an HRSD score ≤7, response as a ≥50% reduction in HRSD score and partial response as a ≥25% reduction in HRSD score. As pilot studies are not formally powered to assess effect, significance levels are not provided.

Results

Six patients with unipolar depression and one patient with bipolar depression participated. On average, participants had used four antidepressant medications during the current MDE. All had received augmentation treatment during the current MDE, five had received ECT and four had also received psychotherapy. The average duration of the current MDE was 5.3 years (Tables 1 and 2). For case descriptions, see Supplementary material available at [https://doi.org/10.1192/bjo.2021.1059](https://doi.org/10.1192/bjo.2021.1059).

Treatment was well-tolerated overall. Although one participant requested dose reduction because of adverse events (headache, dissociation, emotional imbalance and heart palpitations), no participants discontinued treatment prematurely and no serious adverse effects occurred. The incidence of adverse events was calculated by comparing SAFTEE, CAPE and CADSS data during treatment and pre-treatment. Moderate discomforts (SAFTEE) were defined as an increase of ‘not present’ to ‘moderate’, or ‘mild’ to ‘severe’. Severe discomforts were defined as an increase of ‘not present’ to ‘severe’. The onset of new delusional thoughts (CAPE) or dissociative symptoms (CADSS) was defined as a change of ‘not present’ at baseline to ‘present’ during treatment, regardless of the severity. Increase of delusional thoughts or dissociative symptoms was defined as an increase of at least two levels of severity of pre-existing symptoms. We defined the minimum clinically important difference (MCID) as ≥8-point decrease in HRSD score, remission as an HRSD score ≤7, response as a ≥50% reduction in HRSD score and partial response as a ≥25% reduction in HRSD score. As pilot studies are not formally powered to assess effect, significance levels are not provided.

<table>
<thead>
<tr>
<th>Table 1 Sociodemographic and psychiatric characteristics (N = 7)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Characteristics</strong></td>
</tr>
<tr>
<td>Sociodemographic</td>
</tr>
<tr>
<td>Age, years</td>
</tr>
<tr>
<td>Female gender</td>
</tr>
<tr>
<td>Psychiatric diagnosis and history</td>
</tr>
<tr>
<td>Major depressive disorder</td>
</tr>
<tr>
<td>Bipolar disorder</td>
</tr>
<tr>
<td>Psychiatric comorbidities</td>
</tr>
<tr>
<td>Age at onset of first depressive episode</td>
</tr>
<tr>
<td>Number of depressive episodes</td>
</tr>
<tr>
<td>Current depressive episode</td>
</tr>
<tr>
<td>Severity, HRSD score</td>
</tr>
<tr>
<td>Duration, years</td>
</tr>
<tr>
<td>Number of antidepressant drug trials</td>
</tr>
<tr>
<td>Received augmentation treatment</td>
</tr>
<tr>
<td>Received electroconvulsive therapy</td>
</tr>
<tr>
<td>Received psychotherapy</td>
</tr>
<tr>
<td>HRSD, Hamilton Rating Scale for Depression</td>
</tr>
</tbody>
</table>

[Source: doi.org/10.1192/bjo.2021.1059] Published online by Cambridge University Press
<table>
<thead>
<tr>
<th>Case</th>
<th>Gender</th>
<th>Age, years</th>
<th>Psychiatric diagnosis</th>
<th>Age at onset, years</th>
<th>Number of major depressive episodes</th>
<th>Duration of current episode, years</th>
<th>Current episode treatment history</th>
<th>Safety and tolerability</th>
<th>Efficacy (HRSD)</th>
<th>Follow-up week 1</th>
<th>Follow-up week 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Male</td>
<td>54</td>
<td>Bipolar depression</td>
<td>46</td>
<td>2</td>
<td>5</td>
<td>5 antidepressant trials; addition/augmentation of antidepressants/mood stabilisers/antipsychotics; ECT: yes</td>
<td>SAFTEE: drowsiness, fatigue, muscle cramps and stiffness, difficulty urinating, difficulty finding words; CAPE: thoughts of control and persecution; total score before treatment: 3; total score at end of treatment: 3</td>
<td>17</td>
<td>9</td>
<td>−8 (47)</td>
</tr>
<tr>
<td>2</td>
<td>Female</td>
<td>41</td>
<td>MDD, BPD, eating disorder</td>
<td>38</td>
<td>1</td>
<td>3</td>
<td>8 antidepressant trials; addition/augmentation of antidepressants/mood stabilisers/antipsychotics; ECT: no; other: psychotherapy</td>
<td>SAFTEE: abnormal sensations, slurred speech, nausea/vomiting, difficulty finding words, dizziness, potential baseline score missing; sexual dysfunction; CAPE: thoughts of persecution; total score before treatment: 14; total score at end of treatment: 16; CADSS: dissociative symptoms; total score before treatment: 24; total score at end of treatment: 22</td>
<td>34</td>
<td>26</td>
<td>−8 (24)</td>
</tr>
<tr>
<td>3</td>
<td>Female</td>
<td>45</td>
<td>MDD, PTSD, ADHD</td>
<td>12</td>
<td>–</td>
<td>2</td>
<td>3 antidepressant trials; addition/augmentation of antidepressants/mood stabilisers/antipsychotics; ECT: yes</td>
<td>SAFTEE: fluid retention, weight gain, hot flashes, nausea/vomiting, diarrhoea, joint pain; CADSS: dissociative symptoms; total score before treatment: 1; total score at end of treatment: 2</td>
<td>27</td>
<td>26</td>
<td>−1 (4)</td>
</tr>
<tr>
<td>4</td>
<td>Female</td>
<td>41</td>
<td>MDD, personality disorder</td>
<td>26</td>
<td>5</td>
<td>8</td>
<td>5 antidepressant trials; addition/augmentation of antidepressants/mood stabilisers/antipsychotics; ECT: yes; other: psychotherapy</td>
<td>SAFTEE: drowsiness, fatigue, dizziness, excessively sweating, sexual dysfunction</td>
<td>19</td>
<td>10</td>
<td>−9 (47)</td>
</tr>
<tr>
<td>5</td>
<td>Male</td>
<td>36</td>
<td>MDD</td>
<td>14</td>
<td>10</td>
<td>2</td>
<td>2 antidepressant trials; addition/augmentation of antidepressants/mood stabilisers/antipsychotics; ECT: yes</td>
<td>SAFTEE: nightmares, feeling unreal, headache, potential baseline scores missing; nausea/vomiting, abdominal discomfort, constipation, decreased appetite, weight loss, mental decline, apathy; CADSS: dissociative symptoms; total score before treatment: 1; total score at end of treatment: 0</td>
<td>20</td>
<td>21</td>
<td>+1 (5)</td>
</tr>
<tr>
<td>6</td>
<td>Male</td>
<td>80</td>
<td>MDD</td>
<td>67</td>
<td>1</td>
<td>13</td>
<td>6 antidepressant trials; addition/augmentation of antidepressants/mood stabilisers/antipsychotics; ECT: yes; other: psychotherapy</td>
<td>SAFTEE: hallucinations, blurred vision, slurred speech, drowsiness, numbness, ringing in ears, abnormal sensations, potential baseline scores missing; frequent urinating, sexual dysfunction, decreased appetite, increased appetite, difficulty finding words, emotional indifference, hot flashes, strange taste; CAPE: thoughts of control and persecution; total score before treatment: 15; total score at end of treatment: 5; CADSS: dissociative symptoms; total score before treatment: 37; total score at end of treatment: 41</td>
<td>24</td>
<td>22</td>
<td>−2 (8)</td>
</tr>
<tr>
<td>7</td>
<td>Female</td>
<td>64</td>
<td>MDD</td>
<td>12</td>
<td>5</td>
<td>4</td>
<td>1 antidepressant trial; addition/augmentation of antidepressants/mood stabilisers/antipsychotics; ECT: no; other: psychotherapy, chronicity</td>
<td>SAFTEE: muscle cramps and stiffness, sexual dysfunction</td>
<td>24</td>
<td>24</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

Δ indicates the difference in HDRS scores between before and after treatment. HRSD, Hamilton Rating Scale for Depression; ECT, electroconvulsive therapy; SAFTEE, Systematic Assessment for Treatment Emergent Events; CAPE, Community Assessment of Psychic Experiences; MDD, major depressive disorder; BPD, borderline personality disorder; CADSS, Clinician Administered Dissociative States Scale; PTSD, post-traumatic stress disorder; ADHD, attention-deficit hyperactivity disorder.
events occurred. No participants reported ketamine cravings or an urge to use ketamine beyond the prescribed treatment period.

Onset of moderate discomforts or moderate increase of pre-existing discomforts was reported 45 times, and mostly involved sexual dysfunction \( (n = 3) \), difficulty finding words \( (n = 3) \) and nausea/vomiting \( (n = 3) \). Onset of severe discomforts was reported four times, and included sexual dysfunction, drowsiness, numbness and tinnitus. Of those reported, 19% of discomforts were reported after 1 week of treatment, 44% after 2 weeks and 38% after 3 weeks. Most discomforts were self-limiting before the end of follow-up, except for moderate drowsiness and fatigue in one participant, and (subjective) moderate fluid retention and hot flashes in another participant. Onset or increase of delusional thoughts was reported four times, and included thoughts of control and persecution. Onset or increase of dissociative symptoms was reported seven times. Both were mild and self-limiting. Hypertension or tachycardia did not occur.

All participants reported positive effects, including reduction of suicidal thoughts, improved mood and increased energy levels. The mean HRSD score decreased from 23.6 at baseline to 19.7 at week 3 \((-16.5\%)\). Three participants showed absolute reductions above MCID, of whom two showed partial response (Fig. 1). No participants showed full response or remission within the treatment period.

During follow-up, the mean HRSD score increased to 22.8 within 1 week and to 25.4 within 2 weeks. Two participants showed further reduction in HRSD scores during follow-up; however, three participants showed an increase in HRSD scores. Follow-up data for two participants are missing.

### Discussion

This pilot study was conducted to explore the safety, tolerability and potential clinical effectiveness of a 3-week treatment with repeated, low-dose generic oral esketamine. Treatment appeared safe and was well-tolerated. Most adverse events were moderate and self-limiting. Four adverse events had not resolved before the end of follow-up, namely drowsiness and fatigue in one patient and (subjective) fluid retention and hot flashes in another. It is unclear if these symptoms were linked to the esketamine treatment.

Although side-effects are common during treatment with (es)ketamine, little is known about the side-effects of repeated dosing, including possible cumulative and longer-term effects.\(^8\) (Es)ketamine-induced ulcerative cystitis and dependence are of particular concern.\(^25\) Potential tolerance to the drug cannot be ignored, particularly with daily dosing. Preclinical studies have demonstrated a significant escalation of intravenous (es)ketamine intake during repeated self-administration sessions in rats.\(^16,27\) However, tolerance to daily oral ketamine treatment in patients with chronic pain is not often observed.\(^11,28\) This may be because the oral route of administration is associated with a lower risk of misuse in general,\(^12\) and that after oral intake, the main metabolite norketamine reaches higher plasma levels as a result of extensive first-
pass metabolism, and might have a more favourable safety profile than ketamine. Still, when prescribing oral (es)ketamine for patients with depression, the physician is expected to determine the possible risk/benefit ratio for every individual patient. In addition, after initial response, tapering ought to be the principle to limit the risk of long-term side-effects. Taking into account the possible risk of adverse events, we argue that initiation of (es)ketamine treatment should take place in an in-patient or day care setting, and follow-up treatment should be carefully monitored.

The therapeutic effect of oral esketamine in this study was modest, at least compared with that of intravenous esketamine. Although three out of seven participants reached MCID at the end of treatment, no participants showed full response or remission. This might be because our participants are considered among the most difficult to treat. All patients had severe and chronic TRD and high levels of treatment refractoriness, including for ECT. This predicts a poor response to any subsequent treatment. Therefore, we argue that any clinical benefit in this patient category is a major gain. Moreover, our 3-week treatment duration might have been too short to experience esketamine’s full antidepressant effect. Longer treatment could have led to further improvement, underscored by the lack of plateaus in Fig. 1 (specifically, see cases 1, 2, 4 and 6). This would be in line with the findings of Jafarinia et al., showing a significant treatment effect of oral ketamine versus placebo after 6, but not 3 weeks of treatment.

Another potential explanation for the modest therapeutic effect can be found in the treatment regimen. Although first-pass metabolism was taken into account when determining the daily dose, it cannot be ruled out that blood levels of esketamine were insufficient for optimal treatment efficacy. We assumed a bioavailability of oral esketamine of 20%. However, lower bioavailability has also been reported. Consequently, 1.25 mg/kg per day could well be lower than the required dose for optimal antidepressant effects. Further, daily doses were divided into three administrations a day. Although this was done to reduce the risk of side-effects, peak esketamine blood levels needed to trigger a pharmacodynamical cascade may not have been reached. Unfortunately, systematic blood levels of esketamine were not determined. At the same time, there is no good support for the idea that peak blood levels are preferable to more steady blood levels, and antidepressant effects of very low doses of sublingual ketamine have been described. We also note that although three non-responders received intravenous esketamine after completing the pilot, again this did not lead to a response (reduction in severity of symptoms of 0%, 2% and 14%; additional data available on request). This argues against the idea that insufficient blood levels unambiguously explain non-response.

A fourth potential explanation for the modest therapeutic effect is the use of the S- (+) enantiomer. Although it has long been assumed that the majority of ketamine’s antidepressant properties stem from its impact on glutamate neurotransmission through NMDA receptor binding, the concept of NMDA receptor antagonism has been challenged, and various other molecular insights have been gained in the mechanistic pathways of ketamine and its enantiomers. This has recently renewed interest into alternatives like arketamine, and points to a need to directly compare the effects of racemic ketamine and its enantiomers in patients with depression.

This pilot study has several limitations. Inherent to the design, the study lacked a control group, blinding and randomisation. Further, our sample size was small and heterogeneous, with high levels of treatment resistance compared with other trials in the literature. In addition, as previously mentioned, blood levels of esketamine and its metabolites could have provided insight into the cause of the modest therapeutic effects in our patients, and should ideally be included in future studies. Despite these limitations, our results indicate that daily oral esketamine over a treatment duration of 3 weeks is safe and well-tolerated, and that, although the therapeutic effect was modest, it may provide relief from TRD, even in patients with a very poor prognosis. Based on these findings, we decided to design a randomised controlled trial with a treatment duration of 6 weeks and monitoring of blood levels of (nor)ketamine. If safety, tolerability and effectiveness are confirmed, oral esketamine could become a suitable treatment strategy for TRD.

Sanne Y. Smith-Apeldoorn, MD, Department of Psychiatry, University of Groningen, University Medical Center Groningen, The Netherlands; Jolien K. E. Venaert, MD, Department of Psychiatry, University of Groningen, University Medical Center Groningen, The Netherlands; and Department of Mood Disorders, PsyG Haaglanden, Pammassa Psychiatric Institute, The Netherlands; Henricus G. Rube, MD, PhD, Department of Psychiatry, University of Groningen, University Medical Center Groningen, The Netherlands; Department of Psychiatry, Radboud University Medical Center, The Netherlands; Marije aan het Rot, PhD, Department of Psychology, University of Groningen, The Netherlands; Jeanine Kamphuis, MD, PhD, Department of Psychiatry, University of Groningen, University Medical Center Groningen, The Netherlands; Mariet K. de Boer, MD, PhD, Department of Psychiatry, University of Groningen, University Medical Center Groningen, The Netherlands; Robert A. Schoevers, MD, PhD, Department of Psychiatry, University of Groningen, University Medical Center Groningen, The Netherlands; Henricus aan het Rot, PhD, Department of Psychology, University of Groningen, University Medical Center Groningen, The Netherlands.

Correspondence: Sanne Y. Smith-Apeldoorn. Email: s.y.apeldoorn@umcg.nl

First received 31 Mar 2021, final revision 27 Oct 2021, accepted 28 Oct 2021

Supplementary material
Supplementary material is available online at https://doi.org/10.1192/bjo.2021.1059.

Data availability
The data that support the findings of this study are available from the corresponding author, S.Y.S.-A., upon reasonable request.

Acknowledgements
The authors would like to thank all nurses, doctors and psychiatrists at the psychiatric ward for depression at the University Medical Center Groningen who assisted in this project.

Author contributions
R.A.S., M.A.H.R., H.G.R. and M.K.G.B. contributed to the concept and design of the study. S.Y.S.-A., J.K.E.V., M.A.H.R., J.K. and R.A.S. contributed to the interpretation of the data. S.Y.S.-A., J.K.E.V., M.A.H.R., J.K. and R.A.S. contributed to the drafting of the manuscript. All authors provided critical revision. All authors have seen and approved the final version of this manuscript.

Funding
This study was not funded by any organisation other than the University Medical Center Groningen. The contents of this article are solely the responsibility of the authors.

Disclosure of interest
None.

References

https://doi.org/10.1192/bjo.2021.1059 Published online by Cambridge University Press
14 Abdallah CG, Sanacora G, Duman RS, Krystal JH. The neurobiology of depression, ketamine and rapid-acting antidepressants: is it glutamate inhibition or activation? Pharmacol Ther 2018; 190: 148–58.